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This is an exploratory paper of the ethical implications for genomic research and 
mental illness with specific reference to Singapore. Singapore has a unique context 
due to its social and political systems, and although it is a relatively small country, its 
population is religiously and culturally diverse. The issues that we identify here, 
therefore, will offer new perspectives and will also shed light on the existing literature 
on psychiatric genomics in society. We contextualise issues such as risk and stigma in 
the identification and diagnosis of psychosis in the way they relate to Singaporean 
society, and use a current study (LYRIKS) as a case example.  
 
Genomic research has the potential to change significantly he practice of clinical 
medicine if, as expected, fast and inexpensive sequencing becomes a reality. It will 
likely also change how society thinks and acts in respect to multi-factorial diseases, 
conditions, traits, and syndromes that have a genetic component. Genomic research 
already raises a number of ethical concerns relating to the privacy of individuals, 
including the disclosure of research results and incidental findings, surreptitious tests, 
third party access to data, and the re-emergence of genetic determinism. These issues 
are potentially exacerbated when genomics – the study of whole genomes to 
understand complex illness and behavioural traits – is applied to psychiatric research, 
because of the stigma that is often attached to mental illness. In this paper, we discuss 
some of the issues that have arisen in the context of a study in Singapore that is 
currently investigating the genomics and biomarkers of psychosis. We argue that 
although a genomic study rarely creates data that is directly useful to the participant, it 
can have incidental benefits to the individual who is identified during the study as 
being at high risk of developing psychosis and its related states. Understanding these 
potential benefits requires us to examine the implications that this type of research 
may have on public understandings of genomic data and risk. 
Introduction 
There is a growing research literature supporting a clinical model for early-
intervention treatment of those who, through a combination of modalities, might 
strongly be expected to develop clinical psychosis.2,3 This ‘ultra high risk’ (UHR) 
state is often indicated by a prodromal phase before psychotic breakthrough, and 
insights into behavioural changes and biomarkers have enabled timely treatment with 
more favorable clinical outcomes. This paper refers to ongoing genomic research that 
is likely to have a significant impact on mental health by increasing the understanding 
of complex illnesses and the potential implications of linking genomic screening 
within research populations for these prodromal indications. Genomic studies are now 
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alluding to the heritable features of psychiatric illness and the expectation is that the 
genetic indicators may be allied with existing diagnosis tools to provide clinical 
preventative options. This possibility raises important ethical issues in the 
classification of the premonitory phases of psychosis.  
 
However, by focusing on the psychopathology and patho-physiology of ‘at-risk’ states 
of psychosis, the research may also have implications for the timing at which the 
research participant seeks medical advice, his or her own recognition of symptoms, 
and his or her awareness of the significance of a history of familial diagnoses. These 
will also be affected by the public’s understanding of risk and mental illness (here 
referring to, but without distinguishing between: the population of Singapore, its 
cultural enclaves, discrete communities, and the participant’s family) because such 
relationships will shape and influence the context of the participant’s experiences. In 
this paper, we examine mental health and ‘clinical risk’ in the context of a 
comprehensive investigation into the prodromal significance of psychosis that is 
currently underway in Singapore. As part of this study, researchers are focusing on 
identifying biomarkers associated with an ‘at-risk’ status. Rather than addressing the 
well-trodden issues of individual genetic identity, such as privacy or discrimination, it 
is our intention to consider the social implications of refining a clinical ‘at-risk’ 
genomic profile. Our analysis will provide an ethical point of view in respect to the 




Psychiatric disorders have debilitating effects on the individual and their family, and a 
cost to wider society. However, the biological, environmental, and sub-threshold 
clinical features of mental conditions that precede full-blown illness are poorly 
understood.4 Psychoses, such as schizophrenia, begin with a prodromal period of 
altered functioning and symptomology before the onset of threshold illness.5 
Currently, the prodromal phase is identifiable up to 30 months prior to the display of 
symptoms.6 
Understanding causal patterns in psychiatric illness plays a crucial role in patient 
awareness of their condition and in clinical decision-making.7 There have been many 
approaches used in identifying an UHR state. These approaches, which focus on 
altered functioning and symptomology, have contributed to psychiatric tests which 
may identify individuals who are at risk of developing psychosis, albeit with a limited 
degree of confidence due to the potential for false positives, which in turn are related, 
to some extent, to the efficacy of recruitment of potential UHR individuals.8 These 
tests have most recently been combined with research into neuro-cognitive 
biomarkers and experimental brain imaging. Moreover, the latest high-throughput 
genomic analysis techniques, defined in terms of “the study of genes and their 
functions, and related techniques”,9 are now alluding to gene expression profiles that 
can be linked to specific patterns of clinical progression.10 
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Although the significance of genomics for psychiatric medicine is potentially 
substantial, the impact of attributing a genetic basis to certain psychiatric disorders is 
also a concern, especially if the association encourages prejudice towards patients in 
ways that diminishes their self-esteem and social or economic opportunities. The 
genetic provenance of illness may also increase apathy as a manifestation of 
‘determinism’ or ‘essentialism’, which describes a reaction predicated on the notion 
that nothing can be done, or that one is fated to develop a particular illness because of 
genetic ‘hardwiring’.11 Genomic research may also ‘de-stigmatise’ mental conditions 
by showing a ‘shared heritage’: that is, reaffirming the ‘we’ are 99.9%-the-same’ 
claim,12 or, in respect to a persuasive reclassification of psychiatric of disease so that 
communities can move away from the archaic ‘moral’ categories of deficiency.13  
 
Severe psychotic disorders like schizophrenia are stigmatised across many different 
contexts. These disorders are often misconstrued as a socially determined ‘weakness 
of character’ and used to isolate people as inadequate, unlikable, and dangerous.14,15 
As a result of finding clinical and empirical roots for mental illness, we might find 
that people may be more willing to come forward for treatment because it is easier for 
them to pinpoint a biological (and therefore more concrete) basis for their mental 
health problems,16,17 rather than attributing it to a ‘social’ weakness. An illness model 
of mental health is likely to lead to clinical intervention, rather than mere reflections 
upon the struggles (and failures) of social living. 
 
However, in respect to genomic research, predicting health outcomes will largely be 
focused on population effects (for example, the expected reaction of a population to a 
particular drug) rather than an individual’s options and opportunities (which may even 
be obscured). This creates a different ethical perspective from that which analyses the 
implications of genetic research. In many contexts, genetic tests allow individuals to 
make informed decisions about their clinical options, such as avoiding certain risky 
lifestyles or assisting in family planning. For example, a meta-analysis of the 
effectiveness of genetic testing for smoking-related diseases on smoking cessation 
found that the test resulted in higher risk perception and greater motivation to quit 
smoking,18 although some have questioned the proper use of such testing.19 A 
successful outcome is likely to be dependent in part on an individual’s access to 
information (including genetics), as well as positive changes in health-related 
behaviour patterns.  
 
Of note, however, is the predictive nature of genomic studies – that is, how 
population-wide studies will become ‘personal’ in terms of an individual’s heritage, 
and family and community relationships. Thus, we can expect that should genomics 
eventually reveal UHR profiles, clinical tests will one day be used as decision aids in 
personalised diagnosis and treatment. However, what is presently unclear is how 
knowledge of genomic risks will affect the decisions typically made by, and on behalf 
of, prodromal individuals. This is because indications for ‘at-risk’ states are not a 
clinical entity.20 It is also unclear how families or communities may react to states 
which have an uncertain course and prognosis, or how the same information will be 
seized upon by ‘interested’ parties. The concern, therefore, is whether a deceptively 
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simplistic model of psychosis,21 enabled by genomic studies, will reinvigorate 
deterministic ideas.  
 
Genomic Research in Singapore: The Longitudinal Youth at Risk Study 
(LYRIKS) 
 
LYRIKS is a five-year prospective observational study that began in 2009 and is 
being led by the Institute of Mental Health (IMH) in Singapore as part of a multi-
centre and multi-national study in translational and clinical research in psychosis.  
 
The study aims to identify biomarkers of psychosis vulnerability and to develop a 
clinical model that provides strong positive identification of UHR individuals. The 
expectation is that individuals who are identified as UHR may be given prospective 
treatment during the clinically important prodromal stages and thereby potentially 
alter the course of their illness.22 While it must be noted that an ideal genetic marker 
for psychosis would be derived from patient populations rather than at-risk 
populations, this research raises important ethical considerations that need to be 
explored both for this particular context and for future projects.  
 
For this study, researchers have been recruiting a cohort of young individuals aged 
between 14 to 29 years. Participants have been recruited from various sources 
including the IMH, schools, universities, the armed forces, counselling centers, and 
the community at large. Prospective participants are assessed for UHR using the 
Comprehensive Assessment of At Risk Mental States (CAARMS). Those who fulfill 
the criteria for UHR are then asked to participate in the study, and those who do not 
are invited to join the control group. Under informed consent, participants in the study 
group provide blood for genomic and lipidomic analyses, and are followed over two 
years with bi-annual clinical, neurocognitive and neuro-imaging assessments. They 
remain in the study either until they complete the two-year period of observation, 
choose to withdraw, or convert to psychosis.  
 
Addressing ethical issues in LYRIKS for the participant and clinician/ 
researcher relationship 
 
After the assessment for ‘at risk status’, participants found to meet criteria are 
informed that they are at a higher risk of developing a mental illness than the general 
population. They are also informed of any incidental findings, which are assessed to 
be of potential clinical significance by a neurologist who is part of the research team 
for those participants undergoing Magnetic Resonance Imaging. Since to date no 
biomarkers have been identified for psychosis, however, the results of the genome-
wide association studies/gene expression/lipidomics and other imaging parameters are 
not conveyed to the participants. 
 
It is important to understand that while the IMH has a programme for young people 
who are at risk of developing mental illnesses – the Support for Wellness 
Achievement Program (SWAP) - the participants of LYRIKS are from a number of 
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different sources, including other psychiatric out-patient services and self-referrals 
following our outreach campaigns. Thus, only some participants will be undergoing 
treatment. In treatment scenarios, consent is neither sought nor taken by the treating 
clinician, but is taken by a trained researcher aware of the potential for coercion and 
therapeutic misconception. For those participants who are not undergoing any 
treatment, LYRIKS provides a resource brochure that indicates contact numbers of 
various sources of professional help.  
 
In this paper, we focus on the part of the study that will identify genomic 
polymorphisms associated with the development of psychosis and determine their 
predictive value (along with other biomarkers) in the prevention of conversion. The 
LYRIKS raises a number of ethical issues pertaining to informed consent and notions 
of the ‘mature minor’, the duty to provide clinical interventions in research, and the 
separation of research duties, which are discussed elsewhere.23 This part of the study 
will create large amounts of data – including genomic profiles – pertaining to the risk 
that young adults who meet certain conditions face. Notwithstanding the complexities 
that researchers will face in relating such profiles to the prodromal signs of mental 
health, here we address two particular challenges raised by the generation of such data 
in terms of determinism and a specific research cohort.  
 
First, the prodromal signs of individuals who are identified as UHR will be correlated 
with genomic profiles by the research team. Without any interest in identifying these 
individuals, this part of the research is aimed at elucidating the genomic evidence for 
clinical judgments about the severity and likelihood of disease prognosis and 
prevalence. However, as mentioned already, misunderstanding genetic data risks 
misleading perceptions of psychiatric illness. Hence, it is foreseeable that the 
probability of conversion to psychosis will be interpreted and acted upon differently 
according to how the uncertainties of the research instruments are explained and 
subsequently understood. These variances may impact on the success of the predictive 
model.  
 
Identifying clinical, neurocognitive and imaging markers, may also, in some cases, 
pose difficulties in forming a predictive model. For example, should UHR individuals 
be identified at an early enough stage to seek preventative treatment, their condition 
may not develop into psychosis and will thus appear to contradict the findings of the 
predictive model. Consequently, the research team will have to convey to the 
participants and their caregivers the idea of statistical relevance – the kind of 
information that has been the driver for deterministic ideologies in the past - given 
that all invited individuals, on the basis of meeting some of the criteria that might 
increase their risk of developing a mental illness, will prospectively be identified as 
‘ultra high risk’.  
 
Second, the genomic study will potentially reveal data about certain demographics in 
the Singapore population with respect to a complex genetic disease. The implication 
for the LYRIKS is that it will eventually make possible the identification of 
individuals within the population who have ascertainable risk factors that can be 
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linked to the prodromal phase. Such prospective identification may create further 
circumstances of stigma and exclusion on an individual basis. Genomic studies may 
shift the potential assumptions about determinism to populations, especially if genetic 
‘confirmation’ of an illness is likely to lead to social exclusion.  
 
Understanding ‘Risk’, Clinical Data, and Genomics 
 
Diagnosing mental health conditions has potential psychosocial risks for those who 
are told they are ‘at risk’;24 clinically, this might include a ‘potential’, ‘uncertain’, and 
‘possible’ diagnosis. In terms of social harms, we only need look to the implications 
of genetic determinism.25 Despite an outmoded social and political context that 
supported the worst eugenic atrocities, the contemporary ‘ideologically clean’ and 
statistically verifiable idea of genetic determinism has gained some support.26 
Determinism now suggests that some dispositions to behave in certain ways are 
indeed beyond our control and cannot wilfully be changed (including perhaps those 
behaviours resulting from mental health conditions).  
 
If a UHR status results in only certain behaviours, it appears that determinism carries 
a negative weight: we are normatively classifying people’s actions and behaviours in 
terms of what they are (and are not) responsible for. In terms of health, the ‘dice have 
already been rolled’. However, this use of interpretative evidence has, for some, 
resulted in a “fruitless controversy” that can mislead social perceptions about, and 
shape unnecessary interventions in genetic health, because of a fundamental disparity 
about how we are to perceive ourselves as agents: both as autonomous (as genetic and 
ostensibly free beings) and moral (that we can make decisions about how to act) (see: 
Meaney 200127). We can thus also find that an UHR status – although pertaining 
essentially to a risk status – can have positive effects in respect to personal 
opportunities, such as seeking help, watching for early signs, and preventative 
treatment. 
 
Risk may potentially, therefore, affect an individual’s sense of their own prognosis (or 
potential deterioration), in addition to shaping their role in their family and society.  
While some of the various issues we raise below could be applicable to genomic data 
from other diseases as well, creating genomic data in psychosis research has specific 
challenges related to the interest, care, and perception of individuals, their family and 
their caregivers, who are attempting to understand the nature of a UHR status 
generated by such research. Other parties will also want to know the status of 
individuals because of the implications for insurance or work, or out of simple 
curiosity. For the individual, there will likely be degrees of reaction, falling between 
apathy and a desire to find out the chances of developing the disorder, the 
implications of a positive diagnosis, the clinical interventions available to minimise 
developing illness, and approaches that may alleviate or treat the illness should 
progress. However, characterising or labelling people with an at-risk status can 
become stigmatising and can divest individuals of further opportunities. It is also 
possible that awareness of the hereditary factors may fuel prejudice, resentment, or 
hostility within or towards a discrete group.  
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Within the context of LYRIKS, which involves participants of multi-ethnic 
backgrounds vulnerable to existing discriminations and projections, the subject of 
stigma is difficult to address. This issue is to be explored in future qualitative studies 
at the IMH which place an emphasis on the participant’s narratives. Narratives form a 
crucial part of understanding any impact or influence of stigma related to mental 
illness, although it is difficult to be definitive because the distress faced by young 
individuals seeking help in psychiatric clinics is confounded by the nature of their 
symptoms. Internalisation of stigma may be related to the attenuated psychotic 
symptoms or the associated anxiety and depression, and in most cases, stigma is thus 
not introduced by the study.  
 
Furthermore, in addition to the anxiety felt by an individual about his or her own risk-
status, both within and outside a family network, there is a wider concern about how 
data – whether clinically relevant or not – is understood by the public and other 
parties beyond the family or community, such as medical insurance companies, 
commanding officers, employers, and peers. Privacy rights, for example, have been 
campaigned for in ethical discourses that explore arguments about whether genomic 
data should be regarded as an exceptional form of information and knowledge.28 
Much has been made of the inevitability of genetic discrimination and social 
disadvantage. Yet a counter-argument emphasises the need to share genetic 
information across affected populations to increase opportunities for all, which in 
itself is an ethical necessity for achieving a high standard of public health care. The 
ethics surrounding genomic data in psychosis requires a robust level of management 
between various members of research and clinical teams. We will shortly say a little 
more about these groups – individuals, communities and researchers. 
 
Understanding the Role of Researchers 
 
We find that there are a number of important roles that the researchers must undertake 
in addition to conducting their investigations competently and ethically. First, in 
addition to creating genomic data, researchers will make interpretive use of it. This 
use should be accompanied by considerations (and apprehensions) about scientific 
interpretation and clinical translation, and assessment of appropriate ways to facilitate 
communication to the patient (and taking a step back to the current study, the patient 
is also a research participant, which has implications for the dual responsibilities of 
clinician-researchers), and potentially to family members, communities. Finally, 
researchers should consider public engagement because of the wider implications of 
certain findings to populations. 
 
Secondly, researchers who conduct genomic studies should be aware of the 
circumstances that encourage the use of genomic science as a means to demarcate 
population differences. For example, the recent development of an ‘African-
American’ only drug seeks to provide equity to certain members of a particular 
society.29,30 In light of such developments, there is a growing interesting around the 
world in investigating the potential of personalised medicine to reduce the effects of 
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mental illness. At the same time, the difficulty is that underlying social and cultural 
conceptions about mental illness can have “dramatic consequences for help seeking, 
stereotyping and the kinds of treatment structures we create for people with mental 
illness”.31 The efficiency of mental health treatment clearly has grounding in the level 
of research into mental illness. Our case example, LYRIKS, evidences this by 
designing culturally appropriate conditions for confidentiality, especially for minors 
(in Singapore under 21 years of age) when investigating individuals who may be 
UHR. There is an important connection between the underlying social processes of 
the experience of a psychiatric disorder – both for the patient and their caregivers – 
and the subsequent seeking of testing, diagnosis, and ultimately, clinical treatment.  
 
Cultural, philosophical, and religious values contribute to more severe forms of 
stigma. Any research conducted in a multicultural society, such as Singapore, needs to 
be aware of how these shape public responses to science. For example, Yang et al 
identified three stages that a stigma goes through as it evolves: namely, “direct 
individual discrimination, internalisation of negative stereotypes, and structural 
discrimination”.32 Stigma can also lead to social rejection, loss of employment 
prospects and exclusion from health insurance.33 As a result, Chinese Singaporeans 
are far more likely to hide their illness and not seek treatment compared to people of 
other major races in Singapore.34 Another long-lasting aspect of such stigma in 
Singapore is in the context of its consumer-orientated, medical savings account-based 
health system. This affects all kinds of decision-making in health care, and could 
continue to perpetuate stigmas about certain illnesses such as mental health 
conditions.  
 
People who are ‘unwell’, or are identified as being at risk of developing such a 
disorder in the future, might face difficulties in academic and professional growth 
during their lifetime and exclusion from the rest of their community. These issues are 
important because, once contextualised alongside the ethical analysis of perceptions 
about genomic research in mental health, they can be addressed through careful 
micro- (between the researcher and participants) and macro-management, including 
public education and interaction with other parties. This has implications that all 
researchers should be aware of, including those involved with LYRIKS. However, 
these implications are also balanced out through positive effects of a diagnosis.  
 
For example, our sample reveals that individuals with UHR are help-seeking – this is 
also highlighted in the fact that recruitment took place at the clinic for the IMH. This 
could be due to co-morbidities or a drop in functioning, thus they are already exposed 
to the stigma that goes with mental illnesses. An issue, highlighted recently with 
autism, is that in many societies, without a diagnosis treatment becomes impossible - 
due both to ethical concerns as well as to insurance and to managed care issues. Thus 
for some, a diagnosis could be helpful.  
 
In the following sections, we spell out the repercussions of genomic research in three 
phases, and expand upon the notion of risk by exploring perceptions held by the 
individual, the public, and the scientist.  
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1. The Individual’s Perception of Risk 
 
While it is hoped that genomic research will provide genotypic indications that will 
allow for early identification and intervention in the prognosis of psychosis, such 
information is also combined with the individual’s comprehension of the illness and 
their at-risk status. An individual is a relational being. As noted by Kleinman, a given 
medical system contains particular conceptualisations about the human body and does 
“considerably more than name, classify, and respond to illness” when it is placed in 
its socio-cultural context – an inevitable feature of the body as instrumental of the 
‘person’.35 Thus, the implications of statistical probability and clinical diagnosis affect 
not only the belief systems surrounding the nature of cognition and conceptualisation, 
but also relationships and roles that influence the perception of ‘risk’. The perception 
of risk for the individual is then shaped by certain consequences of them being 
clinically classified as high-risk, which must make inferences about the individual’s 
specific context of family and society – the kind of support they receive, whether 
home life is supportive or intolerable, their day-to-day stress, and exposure to social 
and environmental triggers. Therefore, there will likely be divergence between a 
clinical UHR state and an individual’s perception of their own well-being that 
psychiatric management must grasp for optimal treatment. 
 
It follows that the manageable risks that an individual faces personally may become a 
component of a wider ‘at-risk’ population who may now be seen as ‘abnormal’ and 
thus a ‘threat’ to society. Overall, the long-term aim is to counteract negative 
perceptions of mental illness in society by finding a shared understanding of mental 
health and developing appropriate measures to manage illness within a community 
that involves the individuals themselves, professionals (scientists and clinicians), and 
community representatives, and by educating the public that ‘abnormal’ mental health 
is not inevitably to be feared. An initial negative perception of risk can change for the 
individual following the emergence of a more aware, understanding and sympathetic 
‘public’. 
 
The relationship between research and clinical settings also requires control over 
potential ethical conflicts – a concern that is typified in, for example, the ‘therapeutic 
misconception’. McGorry et al argue that the ethical dilemmas in early intervention in 
psychiatry are similar to those occurring in mainstream medicine.36 The prejudice that 
an individual may face, both from medical professionals and the public, is a result of 
segregating psychiatry and psychiatric research as qualitatively different from other 
medical research,37 even though the Diagnostic and Statistical Manual of Mental 
Disorders has (not uncontroversially) established the biomedical model of mental 
illness. The division has been widely criticised, for example, by Ivan Illich in the 
1970s, who argued that the medical establishment of the West – a medical system that 
prioritises an increasingly segregated and biological (natural) view of medicine – 
poses a threat to health by causing individuals to divorce from sickness, pain, and 
death.38  
 
While the increasing medicalisation of disease warrants its own critique, the relevant 
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point for our discussion is that it can also act as a neutraliser in judgements and 
preconceptions about what disease and disease risk means. Because this naturalism 
has yet to infiltrate fully into the domain of psychiatry, psychiatric research and 
clinical psychiatry are not immune to stigmatisations that are prevalent in certain 
societies and this has particular relevance to understandings of risk. However, it is 
only through continued analysis into understanding the risks involved in genomic 
research about psychosis that knowledge will be gained about clinical management, 
which in turn may improve perceptions about psychiatric disorders. 
 
Therefore, the design of the LYRIKS requires us to consider the potential use of 
genomic data on psychosis in the clinical setting with respect to the individual’s 
comprehension of ‘at-risk’, and potential ethical conflicts. Importantly, as recognised 
in the design of the study, some of the participants may require clinical intervention 
during the study because of emerging symptoms and co-morbidity. These possibilities 
illustrate the ‘risks’ that are revealed during the prodromal state and the subsequent  
researcher-clinician responsibilities to act upon the clinical needs of the patients. This 
issue is acknowledged in the research protocol.39  
 
2. Public Perceptions of Genomic Data. 
 
Public perceptions of genomic data, based on society’s collective understanding, are 
an integral part of an individual’s decision-making in terms of determining risk 
(whether to undergo a test) and diagnosis (the conduct of society in respect to an at-
risk condition). Concerns arise over the social consequences that result from how 
information is presented, especially in the context of the implications of identifying 
the genetic components of, for example, psychosis, which relate the mental state of 
the individual to his or her biology and history of epigenetic events. It is important to 
achieve a fine balance between over-simplifying genomic analysis and allowing such 
data to be accessible in a way that enables it to have a positive function for the public.  
 
Yet, increased scientific and clinical knowledge of risks associated with psychosis 
acts as an important caveat to therapeutic translation. In other words, lifestyle is 
contextualised within the realm of a standardised and objectified body40 leading to a 
stronger relationship between individual experiences and the clinical encounter. This 
raises important implications for psychiatric treatment. Improving health outcomes by 
utilising genomic data is a significant function of healthcare. While individuals who 
are identified as being UHR may not necessarily develop a psychotic disorder, 
identifying features of this phase in terms of behaviour and corroborating it with 
genomic data may provide clinicians with better predictive tools that may have 
diagnostic utility.41 Consequently, such research improves clinical practice, which 
increases public confidence and improves the environment in which the UHR 
individual is supported.  
 
This current clinical ambivalence about UHR diagnoses also impacts the translation of 
genomic data into the public arena and influences public opinion. Identifying a 
genetic causal basis of psychiatric disorders isolates genomic data as the source of an 
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individual’s classification as mentally ‘healthy’ or ‘ill’. Consequently, the labels that 
arise in public perceptions of psychiatric disorders are potentially tied to the genomic 
data that defines the boundaries between ‘normality’ and pathology. The public 
perception of genomic data can have a positive effect, in the sense that there is a 
greater awareness and understanding of mental illness and its various causal factors. 
In turn, these factors play a role in encouraging and supporting individuals to seek 
early clinical intervention and thereby prevent further deterioration.  
 
However, there are also negative perceptions when genomic data is associated with 
the presence of certain mental illnesses. For example, 88 per cent of participants in a 
USA nationwide survey interpreted genomic data to be an actual diagnosis rather than 
an assessment of risk for potentially developing schizophrenia.42 This can lead to 
immediate misconceptions, which are often stereotypical and related to prejudice 
against individuals with mental illness. Responsible communication about the nature 
of genomic data is crucial. 
 
3. Scientists’ Perceptions of Genomic Data and the Clinical Setting. 
 
Finally, we turn our attention to the researcher creating the data. Some of the initial 
perceptions and responsibilities associated with genomic data stem from the 
laboratory. With the advent of validated genomic data, the involvement of genetic 
markers is adding to the multifactorial definition of psychosis. In turn, there is a 
greater emphasis on the relationship between genomic data and scientists’ 
perceptions. This is an important point to consider, because within the scientific 
community there are plural and diverse opinions regarding the use of genomic data, 
and the challenge of developing a unified viewpoint may have further consequences. 
For example, the extent to which genomic data is considered as a fundamental 
indicator of risk for psychosis will affect diagnostic criteria. More specifically, the 
presence of certain gene markers will contribute to defining an individual as being 
‘mentally ill’.  
 
Furthermore, a scientific understanding of the nature of genomic data affects the 
classification of the illness as ‘chronic’ or ‘recoverable’, as well as available treatment 
interventions. This is a difference between determinism and treatment. Importantly, 
identifying UHR individuals may overcome stigma because treatment and 
management are opportunities. Moreover, one could avoid the kind of malaise that 
suppresses a desire for treatment, allowing the condition to deteriorate unnecessarily.  
 
The solution is to get patients involved with their treatment by employing an 
‘operational definition’43 that takes into account personal factors, such as the person’s 
relationships and networks, as vital components in remission and/or recovery. A 
recent development is for researchers to involve participants in research, thus 
encouraging commitment to a long-term project and raising the participant’s 
awareness.44 This was a major consideration in the LYRIKS study and efforts were 
made in the protocol to make sure that participation was possible, including the 
involvement of other family members (particularly parents and guardians who would 
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be required to proxy-consent for participation by minors) where appropriate and 
desirable. 
 
Predictive medicine, formed on the basis of scientist’s interpretation of genomic data, 
is also associated with a responsibility to prevent perceptions of ‘bad’ genes or 
reductionist thinking from taking hold. This is particularly crucial when these 
perceptions leave the laboratory, such as in the context of third party handlers of an 
individual’s genetic data, including health insurance companies or employers. In the 
prevention of risk, any potential negative implications of identifying genetic markers 
for psychiatric disorders are initially the responsibility of the scientist.  
 
However, other clinical team members also play a part in the management and 
communication of genomic information. There is a public interest in genomic 
screening if it has a sound scientific basis and a clear rationale. For example, the 
American Medical Association recommends that testing for an untreatable genetic 
illness in children should wait until they are old enough to consent (American Medical 
Association; Opinion 2.131, 2.137, and 2.138). However, this view is contentious. 
One study researching attitudes towards a prospective genetic test for susceptibility to 
major depression showed that for the number of those resisting the test decreased by 
over a third following a facilitated discussion about positive and negative outcomes. 
Significantly, the participants who were prepared to undergo such a test stressed that 
an implicit trust in medical professionals would be required.45 This further emphasises 
that appropriate communication by members of clinical teams and the translations of 
the scientist’s perceptions are necessary for counteracting the risks drawn out in our 




In this paper, we have explored the understanding of risk associated with genomic 
research and the possibility of identifying individuals who are at UHR of developing 
psychosis. We contextualised such research by referring to a current study in 
Singapore and developed a perspective that the nature of risk involved with genomic 
research and testing may be constructed from social and cultural processes. 
Psychiatric disorders such as schizophrenia are associated with particular stigmas, 
which influence an individual’s decision-making. We analysed the perceptions of the 
individual, the public, and scientists about risks associated with a UHR diagnosis.  
 
Questions about genetic determinism and how this is irrevocably linked to 
stigmatisation and discrimination are familiar. Such perceptions underpin the ethical 
issues that accompany proposals such as the identification of UHR individuals. 
However, this paper, as a backdrop for further discussion, raises the importance of 
ensuring that scientific understandings of mental illness are not constructed in such a 
way that the dogmatisms of genetic determinism are revisited. This not only requires a 
sophisticated approach to communicating to the public the predictive limits of 
genomic research in terms of risk profiling, but also requires scientists to be more 
acutely aware of the values that are attached to scientific knowledge, as well as the 
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authority it carries in the public domain, which is inherently political and value-laden. 
Genomic research, then, should focus upon relational aspects in society, and the 
objectification of risk amongst individuals.  
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